“Annual Review | Professor Yang MingDr. Ming Yang: Latest Developments in Systemic Treatment of Biliary Tract Cancer”

2024.03.12
In the field of biliary tract cancer (BTC) treatment, significant advancements have been made recently. BTC is a highly heterogeneous group of malignancies originating from the epithelium of the bile ducts, presenting challenges in treatment and typically leading to short survival periods for patients. Traditionally, the primary treatment for advanced BTC has been chemotherapy. However, recent developments in immunotherapy combined with chemotherapy as a first-line treatment have shown promise. Additionally, a deeper understanding of the genomic and proteomic characteristics of biliary tumors has led to a clearer classification of molecular subtypes and the discovery of several molecular biomarkers. This has spurred active research in targeted therapies for second-line BTC treatment, significantly altering the treatment landscape for this condition.

CDL (co-management of diabetes-liver diseases strategy) Literature Review – January 2024, Issue 12

2024.03.12
Diabetes and liver disease are prevalent chronic conditions in China, with interconnections in terms of pathogenesis, clinical manifestations, diagnostic and therapeutic targets, making their combined management essential for alleviating the burden of these diseases. In support of the development of diabetes and liver disease co-management initiatives in China, this publication Hepatology Digest, collaborates with the co-management of diabetes-liver diseases strategy(CDL) to introduce the CDL Literature Review column. Each month, we share literature related to the mechanisms and advancements in the diagnosis and treatment of diabetes-related liver diseases. We also invite experts in the field to provide commentary, aiming to offer insights and assistance to experts, researchers, and frontline healthcare professionals engaged in scientific research and clinical care.
Annual Review |Dr. Haitao Zhao: Molecular Characteristics, Diagnosis and Treatment, and New Drug Progress and Exploration Prospects in Biliary Tract Cancer

Annual Review |Dr. Haitao Zhao: Molecular Characteristics, Diagnosis and Treatment, and New Drug Progress and Exploration Prospects in Biliary Tract Cancer

2024.03.12
Editor's Note: Although biliary tract cancer (BTC) is relatively rare, it has a higher incidence in the Southeast Asian population, with 50% of patients already in advanced stages at diagnosis and a survival period of less than one year. Its impact cannot be ignored. In 2023, China saw the approval and market launch of the first-line immunotherapy for BTC, instilling confidence in clinical treatment and ushering in a new era of research exploration. To shed light on this, our journal invited Dr. Haitao Zhao, Director of the Hepatology Department at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, to review the latest developments in the molecular characteristics, clinical diagnosis and treatment, and new drug research of BTC. He also provides a macroscopic perspective, outlining directions worth exploring, such as precision and personalized treatment. Additionally, he selects three promising treatment clues, aiming to provide important guidance for future clinical practice and research exploration.

Annual Review | Dr. Guiqiang Wang: Pursuing Clinical Cure for Hepatitis B, Focusing on Advances in New Drug Development

2024.03.12
Antiviral therapy is the primary treatment strategy for chronic hepatitis B (CHB), aiming to inhibit HBV replication, alleviate liver cell inflammation and fibrosis, and reduce the risk of liver failure, decompensated cirrhosis, and hepatocellular carcinoma (HCC). However, there is currently no treatment that can completely clear covalently closed circular DNA (cccDNA) in infected liver cells, which is a major obstacle to achieving clinical cure for CHB. In recent years, with the continuous development and clinical trials of new drugs targeting different points, exploration of new treatment strategies for the clinical cure of CHB is gradually progressing. To this end, this journal invited Dr. Guiqiang Wang from the Department of Infectious Diseases at Peking University First Hospital to share the latest developments in the field of new drug development for the clinical cure of CHB over the past year.
Anticoagulant Therapy for Acute Pancreatitis-Related Splanchnic Vein Thrombosis

Anticoagulant Therapy for Acute Pancreatitis-Related Splanchnic Vein Thrombosis

2024.03.12
The "Hepatology Digest - Liver Vascular Disease Column" is an academic column initiated by Dr. Qixing Shun from the Department of Gastroenterology, Northern Theater General Hospital, in response to the invitation of the editorial department of "Hepatology Digest". It regularly collects and organizes research progress in the field of hepatic vascular diseases. Every two weeks (Wednesday), an important literature is selected for in-depth discussion, aiming to help readers understand the rationale behind clinical research, inspiring clinical and scientific thinking.